Learn how a quality first mindset can drive success in an organization by watching the MDIC "Case for Quality" series. In this session, our VP of Quality Assurance & Regulatory Affairs, Al Crouse, shares his experience and insights along with other industry thought

Today we announced our fourth quarter and full year financial results and provided a business outlook for 2025. We are pleased to share these milestones: -Active US implanting centers increased 25% over prior year end -US HF revenue increased 41% over prior year Q4 -Increased

Thanks to Shelley Hall for her comprehensive review of #Barostim as a device therapy option to improve #heartfailure symptoms during today's "Current and Emerging Novel Device Therapies" session at #THT2025.

New real-world evidence demonstrated large and statistically significant reductions in hospital visits and length of stay in #Barostim patients with #heartfailure and reduced ejection fraction in a recently published study in the Journal of Cardiac Failure.1,2 See the evidence:

Attending #ACC25 next weekend? Visit us at booth #9005 to learn about #Barostim - a novel device therapy that targets the neurohormonal pathway to significantly improve #heartfailure symptoms. ISI: barost.im/ISI

Beyond thrilled and grateful to join Johns Hopkins Medicine for my #Dermatology residency! Endless gratitude to my mentors who made this possible. To IMGs: keep pushing! Your goals are within reach. #match2025

At #ACC25 this year? Make sure to visit us this weekend (Booth #9005) to learn how #Barostim - an innovative device that targets the neurohormonal pathway - can significantly improve exercise capacity and quality of life in patients with #heartfailure beyond GDMT alone.

Kicking off day 2 at #ISHLT2025! Drop by our booth to learn how #Barostim targets the neurohormonal pathway to improve symptoms in patients with #HFrEF. And be sure to join our symposium on Tuesday at 11:45 AM in room 312.

Congratulations to the members of the SWIFT-HF research group on their new publication in Heart Failure Reviews, "Beyond GDMT: Bridging the Therapeutic Gap in Heart Failure".

“The win-win of this procedure is that it’s low-risk, easy recovery, and produces results. Roughly 90% of our implanted patients reported seeing improvements in their heart failure symptoms. Heart failure medications have survival benefits but don’t give you much quality-of-life

Enhance your knowledge about #Barostim and its role in #heartfailure management through this #ACCEd virtual course. Take the course to learn about: -The stages of heart failure where Barostim is useful -Patient selection criteria -How Barostim complements guideline-directed

We are grateful for the over 75 physicians, nurses, and advanced practice providers who attended our two educational summits over the weekend. Our Friday APP Summit was facilitated by Dr. Manuel Perez-Izquierdo, Melissa Wendell, NP, Andrea Wallace, NP, and Michael Gajewski, NP,

Happening tomorrow! Don't miss our webinar where Philip Adamson, MD, Melissa Wendell, FNP-BC, and Michael Gajewski, AGACNP will explore the APP's critical role in managing #Barostim patients. Discussions will include: -Identifying the right patients -Staging treatment options

We’re pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures

Thank you to esteemed faculty, Shelley Hall, Dr. Rachel Garcia, Andrea Wallace, MSN, FNP-C, HF-Cert, FHFSA, and Richa Gupta, for sharing their real-world experience and invaluable insights on #Barostim, and to the #HFSA2025 attendees for contributing to the engaging